Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesObstetrics/GynecologyAetna vaginitis diagnostic coverage update | OpenP…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0643

    Diagnosis of Vaginitis

    Customize your policy alerts

    Sign up for Aetna Policy 0643 alerts

    Get alerted when Policy 0643 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical policy governing diagnostic testing for vaginitis in symptomatic women, including recommended and investigational tests, intended for providers and payers.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerAetna
    PolicyDiagnosis of Vaginitis
    Policy CodePolicy 0643
    Change TypeNo material change
    Effective DateAug 20, 2002
    Last ReviewJan 3, 2024
    Next Review DateJul 11, 2024
    Key ActionOrder nucleic acid, DNA probe, pH/amine, or sialidase testing only when the patient has symptoms of vaginitis or specified risk factors and document clinical indications.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3major pathogens listed
    3 of 4Amsel threshold
    up to 94%DNA/PCR sensitivity
    Affirm VP IIIoffice DNA probe example
    47references

    Coverage Criteria for Diagnostic Testing of Vaginitis

    NGS and Investigational Methods

    Next-generation sequencing (NGS) and other emerging molecular or multiplexed methods for diagnosing vaginitis are addressed below.

    ALL of the following

    • NGS (next-generation sequencing) methods that profile the vaginal microbiome are considered investigational/experimental for routine clinical diagnosis of vaginitis because clinical utility, standardized interpretation, and analytic performance characteristics have not been established.

      Studies show promise but have limitations including indirect comparisons, lack of analytic validation, high cost, and complex interpretation (Hong et al. 2016).

    • NGS may detect a broader range of organisms (bacteria, fungi, protozoa) and can show good agreement with DNA probe assays in research settings, but intermediate Nugent score groups may be indistinguishable and clinical decision thresholds are not standardized.
    • NGS and other investigational methods should not replace guideline-recommended diagnostic approaches for symptomatic patients (e.g., Amsel criteria, Nugent Gram stain, or validated NAATs) until clinical validity and utility are established.

    Coding and Diagnostic Criteria

    Covered CPT Codes (if selection criteria met)CPTCovered
    0353UInfectious agent detection by nucleic acid (DNA), Chlamydia trachomatis and Neisseria gonorrhoeae, multiplex amplified probe technique, urine, vaginal, pharyngeal, or rectal, each pathogen reported as detected or not detected.
    82120Amines, vaginal fluid, qualitative.
    83986pH, body fluid, except blood.
    87210Smear, primary source with interpretation; wet mount for infectious agents (eg, saline, India ink, KOH preps).
    87480Infectious agent detection by nucleic acid (DNA or RNA); Candida species, direct probe technique.
    87491Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique.
    87510Infectious agent detection by nucleic acid (DNA or RNA); Gardnerella vaginalis, direct probe technique.
    87591Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique.
    87660Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginialis, direct probe technique.
    87661Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, amplified probe technique.
    1–10 of 21
    1/3
    Cytopathology / Screening codes not covered for indications listedCPTNot Covered
    88141-88155Cytopathology, cervical or vaginal.
    88164-88167Cytopathology, slides, cervical or vaginal.
    88174-88175Cytopathology, cervical or vaginal.
    HCPCS not covered for indications listedHCPCSNot Covered
    G0123-G0124Screening cytopathology, cervical or vaginal.
    G0141-G0148Screening cytopathology, smears, cervical or vaginal.
    P3000-P3001Screening papanicolaou smear, cervical or vaginal.
    Q0091Screening papanicolaou smear, obtaining, preparing and conveyance of cervical or vaginal smear to laboratory.
    Not covered - vaginal pathogen panel (27 organisms)CPTNot Covered
    0330UInfectious agent detection by nucleic acid (DNA or RNA), vaginal pathogen panel, identification of 27 organisms, amplified probe technique, vaginal swab.
    ICD-10 Codes covered if selection criteria metICD-10Covered
    A59.01Trichomonal vulvovaginitis.
    B37.31Candidiasis of vulva and vagina (C. albicans).
    B37.32Candidiasis of vulva and vagina (other Candida).
    B96.89Other specified bacterial agents as the cause of diseases classified elsewhere [Gardnerella vaginitis].
    F11.10-F11.19Nondependent abuse of drugs [injection drug use].
    F11.20-F11.229Drug dependence [injection drug use].
    L29.2Pruritus vulvae.
    L29.3Anogenital pruritus, unspecified.
    N76.0Acute vaginitis.
    N76.1Subacute and chronic vaginitis.
    1–10 of 16
    1/2
    ICD-10 Codes not covered for screening indicationsICD-10Not Covered
    Z11.2Encounter for screening for other bacterial diseases.
    Z11.3Encounter for screening for infections with a predominantly sexual mode of transmission.
    Z11.8Encounter for screening for other infectious and parasitic diseases.
    Z13.89Encounter for screening for other disorder.
    Z33.1Pregnant state, incidental.
    Z34.00-Z34.93Encounter for supervision of normal pregnancy.
    Z86.19Personal history of other infectious and parasitic diseases.
    Key clinical threshold
    Amsel's criteria thresholdDiagnosis of BV when >= 3 of 4 criteria are present

    Provider Actions, Documentation, and Prior Authorization Notes

    Prior Authorization

    Cover PCR/multiplex NAATs for symptomatic vaginitis

    PCR and multiplex amplified-probe and NAAT tests (including listed CPT codes such as 0353U, 0352U, 81513, 81514, 87481, 87511, 87660, 87661) are considered medically necessary and covered when the patient has symptoms of vaginitis or specified risk factors (see coverage criteria).

    • Covered for symptomatic women or when selection criteria/risk factors are present.
    • Examples of covered assays include BD MAX vaginitis panel, Aptima BV, NuSwab VG, OneSwab BV Panel, SureSwab BV.
    Note

    No explicit prior authorization statements for custom PCR panels

    The policy text does not state plan-level prior authorization requirements for the described tests; custom multi-organism PCR panels (e.g., Bridge Diagnostics OpenArray) are described as investigational but payer prior authorization rules are not specified here.

    • Bridge Diagnostics OpenArray vaginal pathogen panel is listed in the document as a custom assay (see investigational description).

    Background

    Vaginitis is a common gynecologic condition most often caused by Trichomonas vaginalis, Candida species, or bacterial vaginosis (BV). BV represents an overgrowth of anaerobic bacteria with loss of lactobacilli and elevated vaginal pH. Diagnosis commonly relies on clinical criteria such as Amsel's criteria (≥3 of 4) or laboratory reference methods (Gram stain/Nugent score); molecular assays (DNA probe or PCR) and tests like BVBlue or sialidase activity assays are available and may offer higher sensitivity than wet mount microscopy, particularly for symptomatic patients.

    Definitions and Diagnostic Tests

    Amsel's criteria
    Amsel's diagnostic setDiagnosis of BV is made when at least 3 of the following findings are present: thin, white, homogeneous discharge; clue cells on wet mount; vaginal pH >4.5; fishy odor on addition of 10% KOH (positive amine test).
    Use contextAmsel criteria are an accepted clinical diagnostic approach and may be used when Gram stain/Nugent is not available.
    Relation to symptomsDiagnosis based on Amsel requires clinical symptoms and examination findings; BV may be asymptomatic in ~50% of women.
    DNA probe / PCR testing
    DefinitionMolecular assays detect pathogen-specific nucleic acids (DNA/RNA) and have higher sensitivity than wet-mount microscopy for Trichomonas, Candida, and BV-associated organisms.
    Examples of assays
    Policy Summary
    PayerAetna
    PolicyDiagnosis of Vaginitis
    Policy CodePolicy 0643
    Change TypeNo material change
    Effective DateAug 20, 2002
    Last ReviewJan 3, 2024
    Next Review DateJul 11, 2024
    Key ActionOrder nucleic acid, DNA probe, pH/amine, or sialidase testing only when the patient has symptoms of vaginitis or specified risk factors and document clinical indications.
    SourceLink
    On This Page
    Coverage Criteria for Diagnostic Testing of VaginitisCoding and Diagnostic CriteriaProvider Actions, Documentation, and Prior Authorization NotesBackgroundDefinitions and Diagnostic Tests
  1. This bulletin does not enumerate payer-specific prior authorization steps for custom panels.
  2. Prior Authorization

    Follow plan-specific prior authorization processes

    Consult your plan-specific prior authorization processes — Clinical Policy Bulletins are intended to assist in administering benefits but do not themselves grant coverage or describe payer authorization workflows.

    • Clinical Policy Bulletins are descriptive and may be updated; check member contract and payer prior authorization portal for requirements.
    Note

    Start with microscopy/pH/amine testing; use molecular tests as indicated

    Use office microscopy (Amsel criteria, wet mount), vaginal pH and amine testing as established initial diagnostic approaches; DNA probe or PCR testing may be used as an alternative or when microscopy is inconclusive or higher sensitivity is desired.

    • Amsel's criteria (≥3 of 4) and Gram stain/Nugent remain reference methods; molecular assays are supported for symptomatic patients.
    • DNA probe tests (e.g., Affirm VP III) provide higher sensitivity compared with clinician microscopy.
    Step Therapy

    Step therapy not specified — molecular testing may follow/replace in‑clinic tests

    No formal step-therapy sequence is specified in this bulletin; molecular testing may follow or replace clinician in‑clinic testing for symptomatic patients per guideline context.

    • CDC guidance: BV NAATs should be used among symptomatic women only.
    • Routine stepwise authorization requirements are not described in this excerpt.
    Note
    Documentation Required

    Document clinical indication when ordering molecular tests

    When ordering nucleic acid, DNA probe, or PCR testing, document the patient's clinical symptoms of vaginitis or the presence of listed risk factors to demonstrate that selection criteria for covered CPT codes are met.

    • Document symptoms such as vaginal discharge, odor, or itch and any applicable risk factors (e.g., new/multiple partners, history of STDs).
    • Link documentation to the specific test ordered and the covered CPT/ICD-10 code rationale.
    Documentation Required

    Document diagnostic method (Amsel, Nugent, Hay/Ison) used

    When using referenced diagnostic methods, document the specific method employed (e.g., Amsel criteria, Gram stain with Nugent scoring, Hay/Ison grading) in the medical record.

    • Record Amsel findings (which require ≥3 of 4 criteria for BV diagnosis) or the Nugent/Gram-stain result where performed.
    • Note that guidelines identify Gram stain as gold standard and recommend Amsel if Gram stain unavailable.
    Note

    Provider responsible for medical advice; CPBs are guidance only

    Treating providers are solely responsible for medical advice and treatment; Clinical Policy Bulletins provide general descriptions of plan benefits and do not substitute for clinical judgment.

    • Use the bulletin as a guide for benefit administration, but base clinical decisions on provider judgment and current clinical guidance.
    Denial Risk

    Pap smear for Candida vulvovaginitis is investigational — denial risk

    Use of a Pap smear (cervical cytology) for diagnosis of Candida vulvovaginitis is considered experimental/investigational and is not supported for this indication.

    • Pap tests have low sensitivity for BV and cervical Pap tests have no clinical utility for BV diagnosis per CDC.
    Denial Risk

    Routine screening in asymptomatic women not covered — denial risk

    Routine cytopathology/screening tests for asymptomatic women (codes such as G0123–G0148, P3000–P3001, Q0091 and related cytopathology codes) are not covered for the indications listed and may be denied when used for screening asymptomatic patients.

    • Routine screening for Candida and Gardnerella in asymptomatic women is considered experimental/investigational and not covered.
    • Cytopathology screening codes are listed in the CPB as not covered for the specified indications.
    Denial Risk

    Limit NAAT/PCR use to symptomatic patients — potential denial risk if used for screening

    NAATs and PCR tests for bacterial vaginosis are recommended for symptomatic women only; use among asymptomatic women has undefined accuracy and may be challenged during claims review.

    • CDC: BV NAATs should be used among symptomatic women only (e.g., discharge, odor, itch).
    • Clinical utility of PCR in asymptomatic populations is uncertain and may not meet coverage criteria.
    Note

    Policy scope disclaimer — CPBs guide benefits but are not coverage guarantees

    Clinical Policy Bulletins are developed to assist in administering plan benefits, do not constitute offers of coverage or a contract, and the bulletin may be updated; failure to follow current policy may affect claim adjudication.

    • Check member contract and payer resources for definitive coverage and authorization rules.
    Affirm VP III (DNA probe office test) and lab-based PCR panels (e.g., BD MAX vaginal panel) are cited as examples.
    PerformanceReported sensitivities: DNA tests—for Candida ~80%/98% and for Trichomonas ~88–91%/100%; for BV DNA ~94%/81% (sensitivity/specificity as reported).
    Amsel criteria (clinical)
    Amsel criteria (clinical)Clinical diagnostic criteria requiring at least 3 of 4 findings: thin homogeneous discharge; clue cells on wet mount; vaginal pH >4.5; fishy odor with 10% KOH.
    When to useAccepted when Gram stain/Nugent is not available; recommended by guidelines as an alternative clinical method.
    Notes on asymptomatic casesSymptoms may be absent in ~50% of women with BV; clinical judgment required when applying Amsel criteria.
    Nugent score
    Nugent score interpretationGram-stain–based scoring from 0–10: <4 = normal, 4–6 = intermediate, >6 = bacterial vaginosis.
    Role as reference standardNugent Gram stain is considered the gold standard reference method for BV in guideline-referenced studies.
    Use in studiesUsed as the reference comparator for performance evaluations of molecular and commercial point-of-care tests.
    BVBlue (sialidase activity test)
    Test principleBVBlue detects elevated sialidase activity in vaginal fluid by a color change (blue/green if positive).
    Reported performance versus gram stainReported sensitivity 92.8% and specificity 98% versus gram stain; Sumeksri et al reported 94% sensitivity and 96% specificity versus Nugent.
    Operational noteProvides objective results with <1 minute hands-on time; specimen collection should avoid lubricants on the speculum.
    Vaginal pathogen panel (OpenArray)
    Panel descriptionCustom multiplex real-time PCR OpenArray panel detecting 27 microorganisms associated with BV, aerobic vaginitis, candidiasis, and STIs (eg, Atopobium vaginae, Gardnerella vaginalis, Candida spp., Trichomonas vaginalis, HSV, Chlamydia, Neisseria).
    PlatformImplemented on the OpenArray real-time PCR platform as a multi-target assay obtained via vaginal swab.
    Coverage status noteThis specific 27-organism vaginal pathogen panel is described in the document and is listed as investigational/not covered in policy exclusions.
    Key guideline and diagnostic references
    Scope of referencesReferences include studies and guideline documents on diagnostics for Candida, BV, Trichomonas, and STIs (eg, Schwebke 2018; Workowski et al. CDC guidelines 2010 & 2021; IUSTI/WHO 2018).
    Selected studiesKey citations: Schwebke et al. (2018) on molecular test performance; Sumeksri et al. (2005) on BVBlue performance; Petrikkos et al. on Affirm VP III.
    Guideline sourcesCDC/Workowski STI treatment guidelines and IUSTI/WHO guidelines are cited as diagnostic and management references.